View Older Stories View More Recent Stories
-
Biogen expects $222M charge from research deals in Q4 2025
-
RBC Capital on Biogen (BIIB): 'Competition from assets such as trontinemab remains years away, and not a threat this decade most likely'
-
BIOGEN receives EU approval for high dose SPINRAZA for spinal muscular atrophy
-
4Q25/2026 Biotech Earnings Preview: RBC
-
Biogen (BIIB) PT Raised to $207 at Mizuho
-
UBS Assumes Biogen (BIIB) at Neutral
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
RBC: 'We have just confirmed that a recent clinicaltrials.gov listing for a new drug called BIIB145'
-
Western Digital stock rises after inclusion in Nasdaq-100 Index
-
HSBC highlights one pharma stock to buy and one to sell for 2026
-
HSBC Downgrades Biogen (BIIB) to Reduce
-
Stoke Therapeutics and Biogen present zorevunersen data at epilepsy meeting
-
Eisai and Biogen present data showing LEQEMBI binding to toxic proteins
-
Stoke and Biogen to present zorevunersen data at epilepsy conference
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
-
Biogen partners with Dayra to develop oral macrocyclic peptides
-
Stoke and Biogen publish data showing Dravet syndrome severity
-
Biogen (BIIB): High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
-
Where can biotech stocks go from here? RBC answers
-
Stifel lifts Biogen to Buy, sees potential Alzheimer's narrative shift
-
Stifel Upgrades Biogen (BIIB) to Buy, 'Risk/Reward Shifting Favorably With Clinical Catalysts'
-
Biogen to present felzartamab data at kidney disease conference
-
Biogen (BIIB) PT Raised to $157 at Bernstein SocGen Group
-
Biogen (BIIB) PT Lowered to $250 at Baird
-
Biogen (BIIB) PT Raised to $185 at Guggenheim
-
Biogen (BIIB) Tops Q3 EPS by 93c; updates guidance
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
Biogen licenses oral drug from Vanqua Bio for $70 million upfront
-
Truist Securities: 'Is Biotech Back?!'
-
Biogen expects $2 million charge in third quarter 2025
-
Biotech stocks: Q3 earnings preview
-
Biogen and Stoke present 3-year zorevunersen data for Dravet syndrome
-
Biogen (BIIB) PT Lowered to $217 at RBC Capital
-
Eisai and Biogen launch at-home injection option for alzheimer's drug
-
Jefferies sees 'an attractive setup' in this large biotech stock
-
Jefferies Starts Biogen (BIIB) at Buy
-
Eisai and Biogen receive approval for LEQEMBI in Australia
-
FDA requests technical updates for Biogen's high dose nusinersen application
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Biogen gets European approval for postpartum depression treatment
-
Canaccord Genuity Reiterates Buy Rating on Biogen (BIIB)
-
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
-
FDA approves Eisai's LEQEMBI IQLIK for Alzheimer's maintenance treatment
-
Biogen and Stoke present three-year zorevunersen data for Dravet syndrome
-
Stoke Therapeutics and Biogen present 3-year zorevunersen data for Dravet
-
Stoke Therapeutics and Biogen to present zorevunersen data at epilepsy congress
-
Biogen (BIIB) PT Raised to $118 at Piper Sandler
-
U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
